ENPP1 Inhibitor
Oncology (implied)
Phase 2Active
Key Facts
About Riboscience
Founded in 2016 and based in San Diego, Riboscience is a private, pre-revenue biotech developing novel ribose-derived small molecule therapeutics. The company's core asset is its proprietary Nucleoside Platform, which uses structure-guided design to create drug candidates aimed at unique protein targets in human disease. Its most advanced program is an oral ENPP1 inhibitor in Phase 2 trials, targeting significant unmet needs in oncology and virology, including influenza and Hepatitis B. Riboscience's approach aims to generate first-in-class drugs with improved safety and efficacy profiles.
View full company profile